Start Your Search
P1.01 - Advanced NSCLC (ID 757)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
P1.01-078 - Longitudinal Studies of Quality of Life in Advanced Non-Small Cell Lung Cancer Patients Undergoing First-Line Target Therapy (ID 7871)
09:30 - 16:00 | Author(s): J. Chern
This paper studies the quality of Life (QoL) of taiwan advanced non-small-cell lung cancer (NSCLC) patients receiving first-line target therapy; QoL data into sexual scores using the European Organization for Research and Treatment of Cancer Quality of Life-Core 30 questionnaire EORTC QLQ-C30 and the QLQ-13 in patients with NSCLC.
From March 2016 to March 2017, patients with in a teaching hospital in southern Taiwan were recruited as the research participants, the patients with advanced or metastatic EGFR mutation-positive NSCLC who received gefitinib, erlotinib, or afatinib as first-line treatment, were invited to complete the EORTC QLQ-C30 and QLQ-C13 on a 5 time visit, the data was analyzed by using SPSS 20.0 software.
A total of 30 patients with NSCLC, The global health status showed differences between QOL before Target therapy and 4 and 12 weeks after commencing therapy, compared to baseline. Quality of life-30 scores were 35.6 ± 8.3 before therapy, 38.1 ± 7 after 4 weeks and 43.4 ± 6.8 after 12 weeks (P <0.000)(Table 1). For the other scales, at 12 weeks, improvement of insomnia, Pain, Dyspnoea, Fatigue and Appetite loss, but worsening of diarrhea, Sore mouth and Dysphagia were observed (P <0.05).
Longitudinal QoL assessments are important in advanced lung cancer patients because the data they provide could, for example, help to assess more patient areas and enable early recognition of arising symptom aggravation, there support for case management and health education.Figure 1